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Beneficial effects of baicalein on a model of allergic rhinitis
Allergic rhinitis (AR) is a common disease that causes se-
vere inflammation and even disabilities. Previous studies 
have reported baicalein to have an anti-inflammatory ef-
fect. However, the pharmacological action of baicalein on 
anaphylaxis has not been clarified yet. This study as-
sessed the in vivo protective effect of baicalein post-treat-
ment in an ameliorating ovalbumin (OVA)-sensitized AR 
rat model. Baicalein attenuated histological alterations, 
aberrant tissue repair and inflammation after OVA-in-
duced AR. Baicalein reduced the frequency of nasal/ear 
rubs and sneezes in rats, and inhibited generation of seve-
ral inflammatory cytokines (TNF-α, IL-1β, and IL-6) in 
both blood and nasal lavage of rats. Infiltrations of eo-
sinophils, lymphocyte, and neutrophils were decreased 
in baicalein-administered rats. Furthermore, baicalein 
inhibited the expression of STAT3 phosphorylation in the 
nasal mucosa. In summary, baicalein attenuated OVA-in-
duced AR and inflammation, which suggests it as a promi-
sing therapeutic agent for the alleviation of AR-associated 
inflammation and pathology.
Keywords: baicalein, ovalbumin, allergic rhinitis, inflam-
matory factors, p-STAT3
Allergic rhinitis (AR) is a common allergic disease and an increasing health problem 
in different age groups (1, 2). Although AR is not life-threatening, it frequently co-occurs 
with asthma and atopic eczema, which have negative effects on the patients’ quality of life, 
as well as their academic and job performances (3). AR causes severe pain and has several 
symptoms, such as nasal congestion, sneezing, nasal itching, respiratory obstruction, rhi-
norrhea and nasal overflow. Moreover, prolonged AR can lead to abnormalities in the nasal 
cavity, and severe ear symptoms (4). AR is a chronic disease of the upper respiratory tract 
caused by a complex allergen-induced inflammatory process, which causes inflammation 
of the nasal mucosa. Similar symptoms are caused by the release of histamine, along with 
several cytokines, various proinflammatory mediators and other active substances, which 
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immunoglobulin E (IgE) play a central role in the allergic inflammatory process of AR, and 
in the increase of eosinophils, basophils and mast cell numbers (6). Despite an abundance 
of research on the pathogenesis and symptoms of AR, current treatments cannot reduce 
the occurrence rate of AR. Therefore, innovative and effective strategies are still urgently 
needed for patients with AR. Animal AR models that can be induced by experimental 
administration of ovalbumin (OVA) have been extensively applied to test new drugs (7–9).
Flavonoids, the key bioactive components in Scutellariae radix, are composed of a 
group of natural and low-molecular-weight vegetal products, including oroxylin A, wogo-
nin, baicalein and baicalin (10). These products are renowned for their diverse biological 
activities, such as anti-inflammatory activities. Baicalein has been reported to alleviate 
allergic asthma by adjusting the cytokine imbalance of Th1/Th2 and histamine release in 
mast cells (11). Increasing evidence shows that baicalein has an anti-inflammatory effect in 
mice, alleviating liver inflammation (12), vascular inflammation (13) and colitis induced by 
dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) (14, 15), lipo-
polysaccharide-evoked acute lung inflammation (16), pancreatitis (17) and diet-induced 
non-alcoholic steatohepatitis in mice (18). In this study, a rat model of AR was used to in-
vestigate the regulatory activity of baicalein on the clinical symptoms of AR, mucosal 
histological changes, and inflammation in vivo.
EXPERIMENTAL
Materials
OVA (grade V) was obtained from Sigma (USA), aluminum hydroxide gel was obtained 
from Thermo (USA) and anti-rat IL-6/IL-1β/TNF-α enzyme-linked immunosorbent assay 
(ELISA) kits were obtained from Feiya Biotech (China). Baicalein was provided by Dr Qin-
glong Guo of the College of Pharmacy at China Pharmaceutical University. Antibodies 
against phospho-STAT3 (Tyr705) were obtained from Cell Signaling Technology (USA), 
which were used for immunohistochemical staining at 1:100 dilution. BCA Protein Assay kit 
was purchased from Thermo Fisher Scientific (USA). The kit for immunohistochemical 
staining was obtained from Keygen biotechnology Co., Ltd. (China). Diaminobenzidine 
(DAB) was obtained from Solarbio Science & Technology Co., Ltd. (China). Hematoxylin and 
eosin were purchased from Solarbio Science & Technology Co., Ltd. (China).
Animals
The experimental process was approved by the Committee for Ethical Use and Care 
of Animals of the Jining Medical University. Forty male Sprague-Dawley rats, weighing 
between 200 g and 220 g, were obtained from Jinan Pengyue Experimental Animal Breed-
ing Co. Ltd. (China). The rats were fed in an air-conditioned room at ambient temperature 
of 24 ± 1 °C and relative humidity of 55 ± 5 %, with a 12-hour light-dark cycle.
OVA-induced AR model
Rats were randomly assigned to the following four groups: (1) the saline group (nega-
tive control group, n = 10) was composed of rats that were intranasally challenged with 
saline alone; (2) the OVA group (model group, n = 10); (3) the OVA+baicalein group (drug 
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group, n = 10) was composed of rats that were sensitized, intranasally challenged with 
OVA and administered baicalein before daily intranasal challenge; (4) the OVA+clarityne 
group (positive control group, n = 10), composed of rats that were sensitized, intranasally 
challenged with OVA and administered clarityne before daily intranasal challenge.
After acclimatization to laboratory conditions for one week, 30 rats were sensitized intra-
peritoneally with OVA (0.3 mg) as antigen, in addition to aluminum hydroxide (30 mg) in 
saline (1 mL intraperitoneally) every two days for 16 days. At stage two, all 30 sensitized rats 
were used to develop an AR model by repeating daily intranasal injections with 20 mg mL–1 
OVA of 10 μL via a micropipette for 21 days. The 10 rats in the OVA+baicalein group received 
an intragastric injection of 40 mg kg–1 baicalein dissolved in 0.9 % physiological saline 30 min 
before OVA administration on the 17th day. In the OVA group, 10 rats were repeatedly 
sensitized and exposed to saline at the same dosage and at times similar to rats in the 
other two groups. In addition, the OVA+clarityne group rats were intragastrically injected 
with 50 mg kg–1 clarityne dissolved in 0.9 % physiological saline 30 min before OVA administra-
tion. The rats were weighed daily and were monitored for nasal symptoms.
Evaluation of symptoms
The real-time and late-phase reactions of all nasally challenged rats were inspected 
on days 1, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35 and 37 after OVA administration. The fre-
quency of nasal rubs, sneezing, and nasal secretion that occurred within 30 min after OVA 
i.n. provocation after challenge was observed, evaluated and recorded by an observer. 
Nasal symptoms were scored as a number (0–3) and graded scores are shown in Table I. 
An aggregate score exceeding five indicated a successful AR model (11).
Collection of serum, nasal lavage fluid and major organs
Rats of each group were administered 10 % chloral hydrate (300 mg kg–1) after 24-h 
stimulation. Rats were fixed on an operating table at an angle of about 45°, the abdominal skin 
was cut to expose the abdominal aorta, and blood was collected into prepared plastic tubes.
The nasal lavage fluid was collected by inserting an epidural catheter about 2 cm into 
one side of the nasal cavity. Then, 1.5 mL saline was slowly injected into the nasal cavity 
and the nasal outflow of liquid was received. The same process was performed on the 
other nasal cavity. In addition, the heart, liver, spleen, lung, and kidney tissues were ex-
tracted from the experimental animals. Finally, the main organs were weighed and the 
relevant coefficients were calculated to detect visceral injuries caused by baicalein.
Enzyme-linked immunosorbent assay (ELISA)
Cytokines IL-6, IL-1β, and TNF-α in serum and nasal lavage fluid were detected by 
ELISA following the manufacturer’s instructions. All tests were conducted in duplicate.
Determination of protein concentration in nasal lavage fluid
The remaining nasal lavage fluid was centrifuged at 1000 × g for 5 min at 4 °C, and the 
cell-free supernatant was kept at –80 °C for the subsequent analysis of protein concentration 
via the BCA Protein Assay kit following the instructions provided by the manufacturer.
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Histopathological evaluation
Rats were killed 24 h after final intranasal challenge at day 38. Their heads were fixed 
in 10 % neutral-buffered formalin for 24 h. Then, their nasal mucosa and nasal septum 
tissues were removed and embedded in paraffin, 4 μm thin-sections were cut, and hema-
toxylin-eosin (H&E) or immunohistochemically stained. Immunohistochemical staining 
against p-STAT3 was performed using standard techniques as previously described (19).
Statistical analysis
All results in the paper are expressed as means of ± SD from parallel triple experi-
ments, unless otherwise specified. Statistically significant differences (analysis of variance 
(ANOVA) and post hoc tests) were analyzed with GraphPad Prism software (GraphPad 
Software Inc., USA). Details of each statistical analysis are provided in figure legends. Dif-
ferences with p values < 0.05 were considered statistically significant.
Fig. 1. Treatment with baicalein and clarityne relieved the symptoms in OVA-induced rats. a) Body 
weights of OVA group, OVA+baicalein group, and OVA+clarityne group were measured, b) scores of 
nasal symptoms within 30 min after the last administration in each group, c) and d) show the num-
bers of nasal scratching and sneezing in OVA-sensitized rats (n = 10) and OVA+baicalein treated rats 
(n = 10).
39
T. Liu et al.: Beneficial effects of baicalein on a model of allergic rhinitis, Acta Pharm. 70 (2020) 35–47.
 
RESULTS AND DISCUSSION
Therapeutic effect of baicalein on AR-induced rats
Body weights of rats did not change significantly in the OVA group, the OVA+baicalein 
group and the OVA+clarityne group (Fig. 1a). After stimulation with OVA for 30 min, the 
frequency of sneezing, nasal scratching and the degree of nasal outflow of rats were re-
corded in each group and then superimposed according to the applied score rule. Relevant 
results are shown in Fig. 1b. Since the total score of all rats exceeded 5, the AR model was 
treated as successful. It is noteworthy that the frequency of sneezing and nasal scratching 
after OVA challenge was higher than in the normal group, manifested as an outflow to the 
face. Moreover, the baicalein-treated groups showed lower frequency of sneezing and na-
sal scratching (Figs. 1c,d). The results showed the differences in the frequency of sneezing 
between the model group and the drug group for the periods of 1–25 days (no drug inhibi-
tion), 27–29 days (drug inhibition) and the 31st day (poor drug inhibition). The exact mecha-
nism remains unclear. The disease could have recurrent symptoms, which counteracted 
the inhibitory effect of the drug on the disease progress; however, the results still showed 
baicalein-mediated inhibitory effect on the frequency of sneezing in general. These results 
showed that baicalein could inhibit the development of allergic rhinitis induced by OVA.
Masses of the main organs (including heart, liver, spleen, lung, and kidney) are shown 
in Fig. 2. The spleen in the model group was statistically significantly heavier than that in 
the control group (p < 0.05), while lighter in the baicalein-treated group compared to the 
model group (p < 0.05). The spleen is involved in the immune response to AR, which indi-
Fig. 2. Mass changes of the main organs: a) spleen, b) lung, c) heart, d) liver, e) kidney in OVA group, 
OVA+baicalein group, and OVA+clarityne group were measured. All data are expressed as means ± 
SD, *p < 0.05, compared to control group; #p < 0.05, compared to OVA group.
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cates that baicalein could reduce spleen damage during inflammation. In addition, no 
differences in other organs (heart, liver, lungs, and kidney) were found between the baica-
lein-treated group and the control group.
Effect of baicalein on protein concentration and the production of IL-6, TNF-α,  
and IL-1β levels in the nasal lavage fluid and serum of AR rats
Protein concentration of the AR model were significantly higher than the levels of rats 
in the control group, whereas those levels were significantly reduced by baicalein (Fig. 3a). 
To assess the adjustment effect of baicalein on the generation of inflammatory factors, the 
production of IL-6, TNF-α, and IL-1β in the nasal lavage fluid of the AR model were mea-
sured. Relevant results are shown in Fig. 3b-d.
Levels of IL-6, TNF-α, and IL-1β in the serum of AR-induced rats were significantly 
increased compared to the levels of the OVA-unsensitized rats, which were diminished by 
the treatment of baicalein (Fig. 4a-c).
Fig. 3. Protein concentration and cytokine secretion in nasal irrigation and serum of AR rats. a) Data 
are expressed as means ± SD, *p < 0.05, **p < 0.01 compared to control group; #p < 0.05, ##p < 0.01 com-
pared to OVA group. ELISA assessment shows secretion of: b) IL-1β, c) IL-6 and d) TNF-α (n = 10 in 
each group). All data are expressed as means ± SD. *p < 0.05, **p < 0.01 compared to control group; #p 
< 0.05, ##p < 0.01 compared to OVA group.
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Effect of baicalein on inflammatory cell infiltration in both nasal mucosa tissues  
and lung tissues
Allergen challenge caused extensive inflammatory infiltration in the lamina propria, 
and the overlying epithelium was occasionally observed. Histological findings of H&E 
staining in the nasal mucosa sections are shown in Fig. 5. The normal group showed no 
inflammatory cell infiltration in the nasal cavity, nasal septum and lateral nasal walls. In 
addition, the connective tissue structure was normal, both vascular congestion and prolife-
ration disappeared, and mucosal glands and chondrocytes were normal. Notable changes 
were found in all histological parameters in the model group. H&E staining indicated that 
the respective numbers of inflammatory cells (including eosinophils, lymphocyte and 
neutrophils) in the nasal mucosa of AR rats were high. The frequency of nasal inflamma-
tion was lower in the groups that received baicalein treatment and the positive group 
compared to the AR group. This indicated that baicalein had a marked capacity to inhibit 
inflammatory cell accumulation.
Fig. 4. ELISA assessment showed secretion of: a) TNF-α, b) IL-6 and c) IL-1β (n = 10 in each group). All 
data are expressed as means ± SD. *p < 0.05, **p < 0.01 compared to control group; #p < 0.05, ##p < 0.01 
compared to OVA group.
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Lung tissue samples were collected and the relevant sections were stained with H&E 
to investigate the degree of lung injury. Lung tissues from the model group showed clear 
damage: interstitial edema and abscess formation, thickening of the alveolar wall and in-
filtration of neutrophils into the alveolar wall. However, baicalein could effectively reduce 
these symptoms (Fig. 6).
Effect of baicalein on the expression of p-STAT3 in nasal mucosa tissues
To confirm that baicalein induction was achieved by the inhibition of relevant path-
ways, the effect of baicalein on the STAT3 signaling pathway in the OVA-induced rats was 
Fig. 5. Treatment with baicalein relieved lesions of nasal mucosa tissues in OVA-induced rats. Photo-
micrographs of H&E stained sections of nasal mucosa from each group.
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investigated. The obtained results showed that baicalein inhibited the phosphorylation of 
STAT3 in the nasal mucosa of OVA-induced rats (Fig. 7).
AR is caused by an increasing number of inflammatory cytokines in lesions, which 
cause sneezing, rhinorrhea, and itching (20, 21). During the early phase of AR, the allergen-
IgE could induce activation of inflammatory cells, containing neutrophils, lymphocytes 
and eosinophils, and produce inflammation-related cytokines (including IL-6, TNF-α, and 
IL-1β). During the late-phase of AR, other inflammatory cells are added, containing eosi-
nophils, mast cells, basophils, and T cells, in the epithelium and the deeper lamina propria 
(22–24). Further release of histamine, leukotrienes, chemokines and other compounds 
maintains the anaphylactic reaction (6, 25). In this study, the AR model of rats was estab-
lished by repeated nasal drip OVA application, which exhibited similar allergic symptoms 
in humans; it can be used to analyze the detraction effect of AR (26).
In this study, typical AR symptoms were observed since day 15, which gradually 
disappeared after approximately 1.5 h. The results showed that baicalein reduced the fre-
quency of nasal itching and sneezing of rats with AR. In addition, the in vivo observation 
Fig. 6. Treatment with baicalein and clarityne relieved the symptoms of lung tissues in OVA-induced 
rats. Light photomicrographs of H&E stained sections of lung tissue samples from each group.
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Fig. 7. Effect of baicalein on the expression of p-STAT3 in nasal mucosa tissues of OVA-induced rats. 
a) nuclear expression of p-STAT3 was detected using immunohistochemical staining, b) densitomet-
ric analysis of the expression of p-STAT3 protein in nasal mucosa tissues of OVA-induced rats.
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showed a strong abatement of eosinophils and infiltration of other inflammatory cells into 
the nasal mucosa of rats in response to baicalein treatment. This indicates that baicalein 
injection could effectively relieve nasal allergic symptoms. Baicalein also reversed the in-
crease of inflammatory cytokine production in rats with AR. In summary, baicalein allevi-
ated the allergic inflammatory reaction in this AR model.
It has been reported that STAT3 and Ah can co-regulate the differentiation of Th17 
and Treg cells, and the modulation of STAT3/STAT5 activity rectifies the imbalance of 
Th17/Treg cells (27, 28). Relevant results showed that baicalein inhibited the p-STAT3 ex-
pression in the nasal mucosa of OVA-induced rats. The main limitation of this study is that 
the effects of baicalein on the production of Th17 and Treg cell-related cytokines (such as 
IL-17, IL-21, IL-22, and IL-10) were not studied to investigate whether baicalein could lead 
to a shift of Th17 toward Treg cells. Therefore, a future study will focus on investigating 
whether baicalein may regulate such a shift of Th17 and Treg cells through the STAT3 
signaling pathway. Baicalein is a promising agent to alleviate the symptoms of AR and can 
be developed into new therapeutic agents in the future.
CONCLUSIONS
The present study demonstrated that baicalein attenuated histological alterations, ab-
errant tissue repair, and inflammation after OVA-induced AR. Furthermore, baicalein in-
hibited the generation of several inflammatory cytokines in blood and nasal lavage of rats 
with AR. In addition, baicalein reduced the infiltration of eosinophils, lymphocyte and 
neutrophils. Its action is regulated, at least in part, by a decrease of STAT3 phosphorylation 
and subsequent nuclear translocation.
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